Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Eli Lilly and Company (LLY) announced that its pipeline candidate, tirzepatide, met all primary and key secondary endpoints in two phase III studies evaluating it in adults with obstructive sleep apnea (OSA) and obesity.OSA is a common sleep-related breathing disorder that causes repeated interruptions in breathing during sleep. This can lead to decreased oxygen levels in the blood, causing strain on the cardiovascular system and other organs over time. It can lead to complications like hypertension, corona ...